CTLA4 and cancer: Recent approvals by the US Food and Drug Administration (FDA) of ipilimumab, a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blocking antibody, for the treatment of melanoma5 has encouraged the placement of immunotherapy at the forefront of cancer treatment.